US 10849960
Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
granted A61KA61K35/15A61K38/1793
Quick answer
US patent 10849960 (Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K35/15, A61K38/1793, A61K38/2026, A61K38/212